Biomarkers as Endpoints in Clinical Trials for Alzheimer’s Disease
Journal of Alzheimer’s Disease · 2024
DOI: 10.3233/jad-240008 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Alzheimer’s Disease, 2024. Verfasst von Yomna Elghanam und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health, Evidence-Based and Clinical Research Laboratory, Social, and Clinical Pharmacy, College of Pharmacy, Chung-Ang University, Seou…. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers, Clinical Trials as Topic. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 40 Literaturangaben.
Themen: Demenz
Abstract (Originalsprache)
Background
Alzheimer’s disease (AD) is a neurodegenerative disease that imposes economic and societal burden. Biomarkers have played a crucial role in the recent approval of aducanumab and lecanemab as disease-modifying therapies which marked a significant milestone for the treatment of AD. The inclusion of biomarkers in AD trials facilitates precise diagnosis, monitors safety, demonstrates target engagement, and supports disease modification.
Objective
This study analyzed the utilization state and trends of biomarkers as endpoints in AD trials.
Methods
In this retrospective study, trials were collected by searching clinicaltrials.gov using the term “Alzheimer”. Primary and secondary outcomes were analyzed separately for each phase.
Results
Among the 1,048 analyzed trials, 313 (29.87%) adopted biomarkers as primary endpoints and 364 (34.73%) as secondary endpoints, mainly in phases 1 and 2. The top three biomarkers adopted as primary endpoints in phases 1, 2, and 3 were amyloid-PET, tau-PET, and MRI. The top three biomarkers adopted as secondary endpoints, in phase 1, were cerebrospinal fluid (CSF) amyloid-β (Aβ), blood Aβ and amyloid-PET; in phase 2, they were MRI, CSF Aβ, and CSF phospho-tau; and in phase 3, they were amyloid PET, MRI, and blood Aβ. There was a statistically significant increase in the adoption of biomarkers as primary endpoints in phase 2 trials ( p = 0.001) and secondary endpoints in phase 3 trials ( p = 0.001).
Conclusions
The growing recognition of the importance of biomarkers in AD trial’ design and drug development is evident by the significant steady increase in biomarkers’ utilization in phases 2 and 3.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Health, Evidence-Based and Clinical Research Laboratory, Social, and Clinical Pharmacy, College of Pharmacy, Chung-Ang University, Seoul, Korea.
- The Graduate School for Pharmaceutical Industry Management, College of Pharmacy, Chung-Ang University, Seoul, Korea.
- The Department of Pharmaceutical Regulatory Sciences, Chung-Ang University, Seoul, Korea.
Zitieren
APA
Elghanam, Y., Purja, S., & Kim, E. Y. (2024). Biomarkers as Endpoints in Clinical Trials for Alzheimer’s Disease. Journal of Alzheimer’s Disease. https://doi.org/10.3233/jad-240008
Vancouver
Elghanam Y, Purja S, Kim EY. Biomarkers as Endpoints in Clinical Trials for Alzheimer’s Disease. Journal of Alzheimer’s Disease. 2024. doi:10.3233/jad-240008
BibTeX
@article{Elghanam2024,
author = {Elghanam, Yomna and Purja, Sujata and Kim, Eun Young},
title = {Biomarkers as Endpoints in Clinical Trials for Alzheimer’s Disease},
journal = {Journal of Alzheimer’s Disease},
year = {2024},
doi = {10.3233/jad-240008}
}
EUVIMED